By Professor Michelle Haber

Journal articles

Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM, 2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Marachelian A; Hogarty MD; Flynn A; Liu K; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer C; Norris M; Haber M; Groshen SG; Ziegler DS; Matthay KK, 2018, 'NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10558

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G, 2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007

Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM, 2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056

Khan A; Gamble L; Yu D; Joshi S; Franshaw L; Burns M; Norris M; Haber M; Tsoli M; Ziegler D, 2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', Neuro-oncology, 20, pp. i49 - i49

Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024

Dagg RA; Pickett HA; Neumann AA; Napier CE; Henson JD; Teber ET; Arthur JW; Reynolds CP; Murray J; Haber M; Sobinoff AP; Lau LMS; Reddel RR, 2017, 'Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres', Cell Reports, 19, pp. 2544 - 2556, http://dx.doi.org/10.1016/j.celrep.2017.05.087

Burchill SA; Beiske K; Shimada H; Ambros PF; Seeger R; Tytgat GAM; Brock PR; Haber M; Park JR; Berthold F, 2017, 'Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group', Cancer, 123, pp. 1095 - 1105, http://dx.doi.org/10.1002/cncr.30380

Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906

Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD, 2016, 'Polyamine antagonist therapies inhibit neuroblastoma initiation and progression', Clinical Cancer Research, 22, pp. 4391 - 4404, http://dx.doi.org/10.1158/1078-0432.CCR-15-2539

Lynch JR; Yi H; Casolari DA; Voli F; Gonzales-Aloy E; Fung TK; Liu B; Brown A; Liu T; Haber M; Norris MD; Lewis ID; So CWE; D'Andrea RJ; Wang JY, 2016, 'Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia', Leukemia, 30, pp. 1745 - 1748, http://dx.doi.org/10.1038/leu.2016.24

O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL, 2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879

Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004

Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001

Kim PY; Tan O; Liu B; Trahair T; Liu T; Haber M; Norris MD; Marshall GM; Cheung BB, 2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021

Somers K; Chudakova DA; Middlemiss SMC; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M; Pan S; Cruikshank S; Scandlyn M; Hoang W; Imamura T; Kees UR; Gudkov AV; Chernova OB; Haber M; Norris MD; Henderson MJ, 2016, 'CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements', Oncotarget, 7, pp. 46067 - 46087, http://dx.doi.org/10.18632/oncotarget.10022

Vittorio O; Brandl M; Cirillo G; Kimpton K; Hinde E; Gaus K; Yee E; Kumar N; Duong H; Fleming C; Haber M; Norris M; Boyer C; Kavallaris M, 2016, 'Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth', Oncotarget, 7, pp. 47479 - 47493, http://dx.doi.org/10.18632/oncotarget.10201

French JD; Johnatty SE; Lu Y; Beesley J; Gao B; Kalimutho M; Henderson MJ; Russell AJ; Kar S; Chen X; Hillman KM; Kaufmann S; Sivakumaran H; O'Reilly M; Wang C; Korbie DJ; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching PA; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Pisterer J; Hillemanns P; Nakanishi T; Yatabe Y; Goodman MT; Lurie G; Matsuno RK; Thompson PJ; Pejovic T; Bean Y; Heitz F; Harter P; Du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan JM; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut JM; Iversen E; Weber RP; Brennan D; Berchuck A; Pharoah P; Harnett P; Norris MD; Haber M; Goode EL; Lee JS; Khanna KK; Meyer KB; Chenevix-Trench G; DeFazio A; Edwards SL; MacGregor S, 2016, 'Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer', Oncotarget, 7, pp. 6353 - 6368, http://dx.doi.org/10.18632/oncotarget.7047

Decock A; Ongenaert M; Cannoodt R; Verniers K; Wilde BD; Laureys G; Van Roy N; Berbegall AP; Bienertova-Vasku J; Bown N; Clément N; Combaret V; Haber M; Hoyoux C; Murray J; Noguera R; Pierron G; Schleiermacher G; Schulte JH; Stallings RL; Tweddle DA; De Preter K; Speleman F; Vandesompele J, 2016, 'Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma', Oncotarget, 7, pp. 1960 - 1972, http://dx.doi.org/10.18632/oncotarget.6477

Xue C; Yu DMT; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD, 2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709

Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T, 2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640

Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675

Koach J; Murray JE; McCarroll J; Milazzo G; Perini G; Haber M; Norris MD; Fletcher JI; Cheung BB; Marshall GM, 2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x

Carter DR; Murray J; Cheung BB; Gamble L; Koach J; Tsang J; Sutton S; Kalla H; Syed S; Gifford AJ; Issaeva N; Biktasova A; Atmadibrata B; Sun Y; Sokolowski N; Ling D; Kim PY; Webber H; Clark A; Ruhle M; Liu B; Oberthuer A; Fischer M; Byrne J; Saletta F; Thwe LM; Purmal A; Haderski G; Burkhart C; Speleman F; De Preter K; Beckers A; Ziegler DS; Liu T; Gurova KV; Gudkov AV; Norris MD; Haber M; Marshall GM, 2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, 7, pp. 312ra176, http://dx.doi.org/10.1126/scitranslmed.aab1803

Cheung BB; Tan O; Koach J; Liu B; Shum MSY; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM, 2015, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, 9, pp. 1484 - 1500, http://dx.doi.org/10.1016/j.molonc.2015.04.005

Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD, 2015, 'Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma', TRANSLATIONAL PEDIATRICS, 4, pp. 226 - 238, http://dx.doi.org/10.3978/j.issn.2224-4336.2015.04.06

Greenop KR; Scott RJ; Attia J; Bower C; De Klerk NH; Norris MD; Haber M; Jamieson SE; Van Bockxmeer FM; Gottardo NG; Ashton LJ; Armstrong BK; Milne E, 2015, 'Folate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control study', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 931 - 937, http://dx.doi.org/10.1158/1055-9965.EPI-14-1248

Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA, 2015, 'Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia', British Journal of Haematology, 168, pp. 395 - 404, http://dx.doi.org/10.1111/bjh.13142

Yu DMT; Huynh T; Truong AM; Haber M; Norris MD, 2015, 'ABC Transporters and Neuroblastoma', , 125, pp. 139 - 170, http://dx.doi.org/10.1016/bs.acr.2014.10.005

Milne E; Greenop KR; Scott RJ; Haber M; Norris MD; Attia J; Jamieson SE; Miller M; Bower C; Bailey HD; Dawson S; McCowage GB; De Klerk NH; Van Bockxmeer FM; Armstrong BK, 2015, 'Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 48 - 56, http://dx.doi.org/10.1158/1055-9965.EPI-14-0680

Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732

Dietrich PA; Yang C; Leung HHL; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY; Gonzales-Aloy E, 2014, 'GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis', Blood, 124, pp. 3284 - 3294, http://dx.doi.org/10.1182/blood-2013-10-532523

Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DMF; Henderson MJ; Cole SPC; Fletcher JI; Haber M; Norris MD, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023

Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; Du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; Defazio A; Norris MD; Macgregor S; Haber M; Henderson MJ, 2014, 'ABCA transporter gene expression and poor outcome in epithelial ovarian cancer', Journal of the National Cancer Institute, 106, pp. dju149, http://dx.doi.org/10.1093/jnci/dju149

Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D; Underhill C, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, pp. 4669, http://dx.doi.org/10.1038/srep04669

Heong V; Topp M; Rutkowski R; Ananda S; Wong S; Swisher E; Lindeman G; Haber M; Norris MD; Haluska P; Wakefield M; Bowtell D; Scott CL; Lindeman G, 2014, 'USE OF NOVEL PATIENT-DERIVED XENOGRAFTS AND MOLECULAR SUBTYPING TO IMPROVE PRECISION MEDICINE IN HIGH-GRADE SEROUS OVARIAN CANCER', EUROPEAN JOURNAL OF CANCER, 50, pp. E9 - E9, http://dx.doi.org/10.1016/j.ejca.2014.03.042

Tee EL; Ling D; Nelson C; Atmadibrata B; Dinger M; XU N; Mizukami T; Liu PY; Liu B; Cheung B; Pasquier E; Haber M; Norris MD; Suzuki T; Marshall GM; Liu T, 2014, 'The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1', Oncotarget, 5, pp. 1793 - 1804, http://dx.doi.org/10.18632/oncotarget.1785

Kim PY; Tan O; Diakiw SM; Carter D; Sekerye EO; Wasinger VC; Liu T; Kavallaris M; Norris MD; Haber M; Chesler L; Dolnikov A; Trahair TN; Cheung NK; Marshall GM; Cheung BB; Sekyere E, 2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032

Dorstyn L; Puccini J; Nikolic A; Shalini S; Wilson CH; Norris MD; Haber M; Kumar S, 2014, 'An unexpected role for caspase-2 in neuroblastoma', Cell Death and Disease, 5, pp. e1383 - e1383, http://dx.doi.org/10.1038/cddis.2014.342

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Saletta F; Wadham C; Ziegler DS; Marshall GM; Haber M; McCowage G; Norris MD; Byrne JA, 2014, 'Molecular profiling of childhood cancer: Biomarkers and novel therapies', BBA Clinical, 1, pp. 59 - 77, http://dx.doi.org/10.1016/j.bbacli.2014.06.003

Saletta F; Wadham C; Byrne J; Ziegler D; McCowage G; Haber M; Marshall G; Norris M, 2014, '421 Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancer', European Journal of Cancer, 50, pp. 135, http://dx.doi.org/10.1016/s0959-8049(14)70547-7

Karsa M; Dalla Pozza L; Venn NC; Law T; Shi R; Giles JE; Bahar AY; Cross S; Catchpoole D; Haber M; Marshall GM; Norris MD; Sutton R, 2013, 'Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease', PLoS ONE, 8, pp. e76455, http://dx.doi.org/10.1371/journal.pone.0076455

Marshall GM; Dalla Pozza L; Sutton R; Ng A; De Groot-Kruseman HA; Van Der Velden VH; Venn NC; Van Den Berg H; De Bont ESJM; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJL; Bierings MB; Van Der Schoot E; Van Dongen J; Law T; Cross S; Mueller H; De Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R, 2013, 'High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation', Leukemia, 27, pp. 1497 - 1503, http://dx.doi.org/10.1038/leu.2013.44

Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; Du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; DeFazio A; Chenevix-Trench G, 2013, 'ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas', Gynecologic Oncology, 131, pp. 8 - 14, http://dx.doi.org/10.1016/j.ygyno.2013.07.107

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2013, 'Cell-based methods for the identification of Myc-inhibitory small molecules', Methods in Molecular Biology, 1012, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18

Sekyere E; Thomas WD; Keating J; Calao M; Cui HJ; Chen JB; Raif A; Jankowski K; Cheung B; Davies NP NP; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM; Haber M; Norris M; Tan O; Chen B; van Bekkum M, 2013, 'Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation', Oncogene, 32, pp. 3616 - 3626, http://dx.doi.org/10.1038/onc.2012.368

Malyukova A; Papa R; O'Brien R; Giles JE; Trahair TN; Pozza LD; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Marshall GM; Giles J, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Liu PY; Xu N; Malyukova A; Scarlett CJ; Sun YT; Zhang XD; Ling D; Su SP; Nelson CA; Chang DK; Koach J; Tee AE; Haber M; Norris MD; Rooman I; Toon C; Xue C; Cheung B; Kumar S; Marshall GM; Biankin AV; Liu T; Shih-Ping Su J; Toon CCW, 2013, 'The histone deacetylase SIRT2 stabilizes Myc oncoproteins', Cell Death and Differentiation, 20, pp. 503 - 514, http://dx.doi.org/10.1038/cdd.2012.147

Back to profile page